» Articles » PMID: 29636521

Exploration of the Effect of Sequence Variations Located Inside the Binding Pocket of HIV-1 and HIV-2 Proteases

Overview
Journal Sci Rep
Specialty Science
Date 2018 Apr 12
PMID 29636521
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

HIV-2 protease (PR2) is naturally resistant to most FDA (Food and Drug Administration)-approved HIV-1 protease inhibitors (PIs), a major antiretroviral class. In this study, we compared the PR1 and PR2 binding pockets extracted from structures complexed with 12 ligands. The comparison of PR1 and PR2 pocket properties showed that bound PR2 pockets were more hydrophobic with more oxygen atoms and fewer nitrogen atoms than PR1 pockets. The structural comparison of PR1 and PR2 pockets highlighted structural changes induced by their sequence variations and that were consistent with these property changes. Specifically, substitutions at residues 31, 46, and 82 induced structural changes in their main-chain atoms that could affect PI binding in PR2. In addition, the modelling of PR1 mutant structures containing V32I and L76M substitutions revealed a cooperative mechanism leading to structural deformation of flap-residue 45 that could modify PR2 flexibility. Our results suggest that substitutions in the PR1 and PR2 pockets can modify PI binding and flap flexibility, which could underlie PR2 resistance against PIs. These results provide new insights concerning the structural changes induced by PR1 and PR2 pocket variation changes, improving the understanding of the atomic mechanism of PR2 resistance to PIs.

Citing Articles

Structural Impacts of Drug-Resistance Mutations Appearing in HIV-2 Protease.

Laville P, Petitjean M, Regad L Molecules. 2021; 26(3).

PMID: 33503916 PMC: 7865771. DOI: 10.3390/molecules26030611.


Impacts of drug resistance mutations on the structural asymmetry of the HIV-2 protease.

Laville P, Fartek S, Cerisier N, Flatters D, Petitjean M, Regad L BMC Mol Cell Biol. 2020; 21(1):46.

PMID: 32576133 PMC: 7310402. DOI: 10.1186/s12860-020-00290-1.


Exploring the Reasons for Decrease in Binding Affinity of HIV-2 Against HIV-1 Protease Complex Using Interaction Entropy Under Polarized Force Field.

Cong Y, Li Y, Jin K, Zhong S, Zhang J, Li H Front Chem. 2018; 6:380.

PMID: 30197882 PMC: 6117221. DOI: 10.3389/fchem.2018.00380.

References
1.
Raugi D, Smith R, Gottlieb G . Four Amino Acid Changes in HIV-2 Protease Confer Class-Wide Sensitivity to Protease Inhibitors. J Virol. 2015; 90(2):1062-9. PMC: 4702657. DOI: 10.1128/JVI.01772-15. View

2.
Sardana V, Schlabach A, Graham P, Bush B, Condra J, Culberson J . Human immunodeficiency virus type 1 protease inhibitors: evaluation of resistance engendered by amino acid substitutions in the enzyme's substrate binding site. Biochemistry. 1994; 33(8):2004-10. DOI: 10.1021/bi00174a005. View

3.
Svetnik V, Liaw A, Tong C, Culberson J, Sheridan R, Feuston B . Random forest: a classification and regression tool for compound classification and QSAR modeling. J Chem Inf Comput Sci. 2003; 43(6):1947-58. DOI: 10.1021/ci034160g. View

4.
Tong L, Pav S, Pargellis C, DO F, Lamarre D, Anderson P . Crystal structure of human immunodeficiency virus (HIV) type 2 protease in complex with a reduced amide inhibitor and comparison with HIV-1 protease structures. Proc Natl Acad Sci U S A. 1993; 90(18):8387-91. PMC: 47361. DOI: 10.1073/pnas.90.18.8387. View

5.
Raugi D, Smith R, Ba S, Toure M, Traore F, Sall F . Complex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy. Antimicrob Agents Chemother. 2013; 57(6):2751-60. PMC: 3716120. DOI: 10.1128/AAC.00405-13. View